Skip to content

Exposure-based therapy for borderline personality disorder: A Randomized Controlled Trial to test the efficacy of a further development of dialectical behaviour therapy (SE-DBT): A pilot study

Exposure-based therapy for borderline personality disorder: A Randomized Controlled Trial to test the efficacy of a further development of dialectical behaviour therapy (SE-DBT): A pilot study - SE-DBT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00027824
Enrollment
80
Registered
2022-01-18
Start date
2022-02-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F60.31

Interventions

Group 1: Structured Exposure Dialectical Behavior Therapy (SE-DBT) The therapy rationale for SE-DBT (Structured Exposure - DBT) is based on the BPD model of DBT (biosocial theory), as well as on their
skills group and patient manual
consultation team). In contrast to S-DBT, SE-DBT aims at an early, structured and fundamental treatment of dysfunctional emotion processing. The focus is on formalized, repeated in-sensu exposure to
exposure
follow-up). In contrast to S-DBT, in which the respective treatment focus is based on the patients current behavioral patterns (event-based focus), SE-DBT is based on a sequential treatment protocol.

Sponsors

Klinik für Psychosomatik und Psychotherapeutische Medizin; Zentralinstitut für Seelische Gesundheit
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: a) 18–65 years of age, b) meets DSM-5 criteria for BPD, c) possibility to attend to online therapy for 12 months d) proficient in English, and e) consents to study participation

Exclusion criteria

Exclusion criteria: a) meets diagnostic criteria for a psychotic disorder, bipolar I disorder, posttraumatic stress disorder, b) body mass index below 17.5, severe substance use disorder or alcohol use disorder that is not in remission in the past three months, or dementia, c) IQ less than 70, or d) has received more than eight weeks of standard DBT treatment within the past year.

Design outcomes

Primary

MeasureTime frame
a) Acceptability of Intervention Measure (AIM) is a 5-item scale that measures the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. It will be completed online at each three-month interval during the treatment b) Client Satisfaction Questionnaire-8 (CSQ-8) is a self-administered questionnaire with items inquiring about respondents’ opinions and conclusions about services they have received or are currently receiving. Response options are based on a four-point scale. It will be completed online at each three-month interval during the treatment c) Telehealth usability questionnaire (TUQ) evaluates the usability of telehealth implementation and services. It contains 20 items rated on a 5-point scale. It will be completed online at each three-month interval during the treatment d) Borderline Symptom List – 23 (BSL-23)26 is a self-report questionnaire that assesses BPD-specific symptoms. It contains 23 items rated on 5-point scale from 0 (not at all) to 4 (very strong) and yields a total score (range 0–115). It will be completed online at each three-month interval during the treatment All primary outcomes assessments conducted at pre-treatment and at three-month intervals up to 12 months

Secondary

MeasureTime frame
Clinician-administered Interviews: Diagnostics: International Personality Disorder Exam (IPDE - BPD subsection); Mini International Neuropsychiatric Interview for DSM-V (MINI) to assess comorbidities Longitudinal (Baseline, 3months, 6months, 9months, 12months (post)): Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) Columbia Suicide Severity Scale (C-SSRS) Acute Suicidal Affective Disturbance Interview (ASAD-I) Questionnaires: Assessed once at baseline: Invalidating Childhood Environment Scale (ICES); Childhood trauma questionnaire (CTQ); Demographic Data Schedule (DDS); Test of Premorbid Functioning (TOPF) in Canada and Mehrfachwahl Wortschatz Intelligenztest (MWT) in Germany; Personality Inventory for DSM-5 Faceted Brief Form (PID-5-FBF); Questionnaire of Unpredictability in Childhood (QUIC) Assessed at every three months during the treatment (Baseline, 3months, 6months, 9months, 12months post-treatment): Acute Suicidal Affective Disturbance Inventory-Lifetime (ASADI-L); Symptom Checklist-27 (SCL-27); Deliberate Self-Harm Inventory (DSHI); Dissociative Symptoms Scale (DSS); State-Trait Anger Expression Inventory-2 (STAXI-2); UCLA Loneliness Scale; Rosenberg Self Esteem Scale (RSES); Level of Personality Functioning Scale - Brief Form 2.0 (LPFS-BF); WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)- 12-Item Version; Difficulties in Emotion Regulation Scale – 16 item version (DERS-16); Working Alliance Inventory-Short Form (WAI-S); Fears of Compassion Scale (FCS); Social Connectedness Scale Revised (SCS-R); Test of Self-Conscious Affect-3 (TOSCA); Rejection Sensitivity Questionnaire (RSQ); Need to Belong Scale (NTB); Aspects of Identity Questionnaire (AIQ-IV); Social Network Index (SNI); Recovering Quality of Life – 20 (ReQoL-20); Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF); Meaning of Life Questionnaire (MLQ); Self-Compassion Scale (SCS); Kentucky Inventory of Mindfulness Skills (KIMS) Exp

Countries

Canada, Germany

Contacts

Public ContactRuben Vonderlin

Zentralinstitut für Seelische Gesundheit

ruben.vonderlin@zi-mannheim.de0049 621 1703 4445

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 5, 2026